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Abstract
Background: Reports of reduced pain sensitivity in autism have prompted opioid theories of autism and have practical care
ramifications. Our objective was to examine behavioral and physiological pain responses, plasma b-endorphin levels and
their relationship in a large group of individuals with autism.
Methodology/Principal Findings: The study was conducted on 73 children and adolescents with autism and 115 normal
individuals matched for age, sex and pubertal stage. Behavioral pain reactivity of individuals with autism was assessed in
three observational situations (parents at home, two caregivers at day-care, a nurse and child psychiatrist during blood
drawing), and compared to controls during venepuncture. Plasma b-endorphin concentrations were measured by
radioimmunoassay. A high proportion of individuals with autism displayed absent or reduced behavioral pain reactivity at
home (68.6%), at day-care (34.2%) and during venepuncture (55.6%). Despite their high rate of absent behavioral pain
reactivity during venepuncture (41.3 vs. 8.7% of controls, P,0.0001), individuals with autism displayed a significantly
increased heart rate in response to venepuncture (P,0.05). Moreover, this response (D heart rate) was significantly greater
than for controls (mean6SEM; 6.462.5 vs. 1.360.8 beats/min, P,0.05). Plasma b-endorphin levels were higher in the
autistic group (P,0.001) and were positively associated with autism severity (P,0.001) and heart rate before or after
venepuncture (P,0.05), but not with behavioral pain reactivity.
Conclusions/Significance: The greater heart rate response to venepuncture and the elevated plasma b-endorphin found in
individuals with autism reflect enhanced physiological and biological stress responses that are dissociated from observable
emotional and behavioral reactions. The results suggest strongly that prior reports of reduced pain sensitivity in autism are
related to a different mode of pain expression rather than to an insensitivity or endogenous analgesia, and do not support
opioid theories of autism. Clinical care practice and hypotheses regarding underlying mechanisms need to assume that
children with autism are sensitive to pain.
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Introduction
It has often been stated that individuals with autistic disorder
have reduced pain sensitivity. Parents, caregivers and mental
health professionals have reported that some autistic children
appear to withstand painful stimuli (bumps, cuts, etc.), show
absence of nociceptive reflexes (e.g., absence of hand withdrawal
reflex when burning oneself), or absence of guarded body position
in cases of broken legs or arms. However, nearly all of the support
for this idea is derived from anecdotal reports and limited clinical
observations [1–9]. Despite the paucity of systematic studies of
pain sensitivity and reactivity in autism, the presence of pain
insensitivity in autism has been given added credence through its
inclusion as an associated feature in standard diagnostic texts. In
DSM-IV and DSM-IV-TR ‘‘a high threshold for pain’’ is
mentioned [10,11] while in DSM-III the ignoring of pain is
described [12].
A number of researchers have suggested that excessive brain
opioid activity could explain the apparent pain insensitivity of
autism and contribute to or even determine the pathogenesis of
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e5289autism [4–9]. The opioid theories in autism have been based on 1)
symptom profiles seen in autism, 2) reported therapeutic effects of
opiate antagonists and 3) reported abnormalities in opioid levels
measured in individuals with autistic disorder, such as b-endorphin
(BE). An increase of central BE activity in autism would be
consistent with a purported reduced pain sensitivity and elevated
pain threshold [1,2–4]. There are also apparent symptom
similarities between autism and opiate addiction or behavioral
states following administration of opiate and opioid agents in
animals [13–19]. Autistic children and opiate-addicted organisms
both appear less sensitive to pain, less emotional and asocial.
Additionally, autistic children show stereotyped and self-
injurious behaviors (SIB) which have been suggested to be related
to pain insensitivity and to be mediated by abnormally high levels
of BE [20–23]. It should be noted that opioid peptides interact
with numerous opioid receptor types [23,24], and that BE itself
acts with the similar affinity at mu, delta and epsilon receptors.
The non-selective opiate antagonists naltrexone and naloxone
have been reported to have beneficial effects on autistic symptoms
including SIB, stereotypies, social withdrawal and productive
speech [20,21,23]. However, benefits have not been consistently
demonstrated [24,25] and one study [25] found that naltrexone
actually increased stereotypies in autism.
As shown in Table 1, a large number of studies have measured
levels of plasma BE in autism without reaching a consensus. The
contradictory data concerning plasma BE levels in autism could be
partly explained by methodological problems, i.e. specificity of
immunoassays, small sample size and clinical heterogeneity of
autism. Studies of central opioid levels in autism have also
produced inconsistent results [37,41], with CSF BE levels in
autistics reported to be increased, decreased or similar to controls
(see Table 1). In a study of the relationship between decreased
pain sensitivity and CSF endorphin, mean CSF endorphin fraction
II levels (mainly Met-enkephalin) were reported to be elevated in
autism spectrum disorder [37]. While this study raised important
issues regarding the relationships between analgesia and endor-
phin dependency in autism, pain reactivity was assessed as a
dichotomous variable without distinguishing different clinical
forms of pain reactivity.
The study of pain sensitivity and reactivity in autism is
inherently difficult, but accumulating parallel studies of pain in
children [42–44] in neurological impairment [45,46] and
psychiatric disorders [47], and in mental retardation and
developmental delay [48–51] provide a framework for investiga-
tion. In general, the more recent studies have underscored the
influence of setting, the importance of having multiple raters, the
difficulty in assessing the absolute and perceived magnitude of the
painful stimulus, and the problems presented by limited or unusual
behavioural repertoire when attempting to assess pain sensitivity.
We have carried out the present study in order to clarify issues of
pain reactivity and sensitivity in individuals with autistic disorder, to
examine possible alterations in plasma BE in autism, and to
investigate the potential associations of BE with behavioral and
physiological responses to pain. Behavioral pain reactivity was
examined in children and adolescent with autistic disorder using
extensive behavioral assessments in different observational situa-
tions. Physiological response to pain was assessed by measuring
heart rate changes during venepuncture, while possible alterations
in BE and its potential mediating effects were examined after
measurement of plasma BE levels in large groups of subjects and
across severity subgroups of autistic disorder. The measurement of
plasma BE was undertaken in order to better understand the
potential role of the opioid system in autistic behaviors and pain-
related behaviors in autism. Greater understanding of the
underlying mechanisms could have important implications regard-
ing the treatment and care of individuals with autism. Children and
adolescents were studied due to the inherently greater relevance of
measurement made in younger subjects when studying an early
onset developmental disorder, and due to relevant prior published
reports examining children and adolescents with autism. Plasma BE
was measured due to the invasiveness of cerebrospinal fluid
sampling, because of the lack of demonstrated utility of urine BE
measurements, and due to the existence of several prior reports of
plasma BE concentrations in autism.
Table 1. Studies of Endorphin and Enkephalin Levels in Individuals with Autism.
Study Fluid Autism Group (N)Opioid Results
Weizman et al. 1984 [26] Plasma 10 Humeral endorphin Decreased compared to normals
Herman et al. 1986 [27] Plasma 5 BE Similar to normals
Weizman et al. 1988 [28] Plasma 22 BE Decreased compared to normals or schizophrenics
Bouvard et al. 1992 [29] Plasma 4 BE Increased compared to normals
Ernst et al. 1993 [30] Plasma 5 BE Similar to normals
Leboyer et al. 1994 [31] Plasma 67 N-terminal BE Decreased compared to normals or girls with Rett’s
Leboyer et al. 1999 [32] Plasma 62 C-terminal BE Increased compared to normals or girls with Rett’s
Bouvard et al. 1995 [33] Plasma 10 C-terminal BE Increased compared to normativecontrol values
Tordjman et al. 1997 [34] Plasma 48 BE Increased compared to normals
Brambilla et al. 1997 [35] PBMC* 12 BE Increased compared to normals or PDD
Cazullo et al. 1999 [36] PBMC 11 C-terminal BE Increased compared to normals
Gillberg et al. 1985 [37] CSF** 20 Met-enkephalin Increased in SIB and low pain sensitivity
Ross et al. 1987 [38] CSF 9 BE Increased compared to normals
Gillberg et al. 1990 [39] CSF 31 BE Decreased compared to normal adults
Nagamitsu et al. 1993 [40], 1997 [41] CSF 19 BE Similar to normals
*PBMC indicates peripheral blood mononuclear cells.
**CSF indicates cerebrospinal fluid.
doi:10.1371/journal.pone.0005289.t001
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objective the examination of associations between behavioral
profiles and biological variables in children with autism. The
larger project included, in addition to the study of plasma BE and
pain-related behaviors, an examination of the relationship
between aggression and plasma testosterone concentrations and
between social withdrawal and platelet serotonin levels.
Methods
Subjects
Children and adolescents with autistic disorder (n=73) were
recruited from child day care facilities of the University Hospital of
Bice ˆtre (Faculte ´d eM e ´decine de Paris-Sud, recruitment by S.
Tordjman M.D., Ph.D.) and of the University Hospital of Reims
(recruitment by M. Botbol M.D., AC Rolland M.D., G Schmit
M.D. and Ph.D.)) and were group matched with normal control
individuals (n=115) on the basis of sex, age and Tanner stage of
puberty as assessed by pediatricians [52]. Demographic data are
given in Table 2.
Based on direct clinical observation by two independent child
psychiatrists, a diagnosis of autistic disorder was made according
to DSM-IV [11], ICD-10, and CFTMEA [54] criteria, and was
confirmed by the Autism Diagnostic Interview-Revised (ADI-R)
[54]. Normal controls, recruited from the preventive medical
center of Reims where they went for a regular check-up, were
determined by two independent paediatricians to be free of
significant psychopathology and any developmental or neurolog-
ical disorders. Additionally, there was no family history of autism
in the control group. All subjects were Caucasian, physically
healthy and had no history of encephalopathy or neuroendocri-
nological disease. All control individuals were unmedicated, while
47 of the patients with autism were unmedicated. Of the 26
medicated patients with autism, 14 patients had a history of
idiopathic epilepsy and were being treated with anticonvulsants,
and 15 patients were receiving neuroleptics. The research protocol
was approved by the ethics committee of Bice ˆtre Hospital and
written informed consent was obtained from parents.
Behavioral and Cognitive Assessments
Cognitive functioning of individuals with autistic disorder was
assessed using the age-appropriate Wechsler intelligence scales
(WPPSI-R, WISC-R, WAIS-R) and the Kaufman K-ABC [55].
All patients were cognitively impaired: mean full scale IQ=42.2,
SD=3.2 (range 40–58).
Behavioral assessments were performed using the ADI-R [54]
and the Pre-Linguistic Behavioral Pain Reactivity Scale (PL-BPRS)
[56]. Autism severity was assessed using the ADI-R, leading to an
overall score of impairments for the combined Social, Communi-
cation and Stereotypy domain (ranging from 1 to 3; the ‘0’ coding
means ‘‘not autistic’’), using a methodology previously described
[57]. Based on ADI-R rating, 52 of the 73 patients with autistic
disorder were identified to be non-verbal. The overall rating of
autistic impairments for each patient was then used to dichotomize
subjects according to autism severity. Individuals were grouped into
mild-moderate (score 1–2) and severe (score 3) impairment. Inter-
judgereliabilitywith respecttothecriticaldistinctionbetween mild/
moderate and severe impairment was excellent, with an inter-judge
agreement of 95% observed between the two expert raters. The PL-
BPRS assessed behavioral pain reactivity by rating the patients’
apparent and observable reactions to noxious stimuli. This scale is
qualitative, categorizing behavioral pain reactivity in 5 classes
summarizedin Table 3. Additionally, the typeof accidental painful
stimulus (burn, painful illness, cut, pinch, etc.) was noted. Painful
stimuli provoked by SIB were not considered. The PL-BPRS has
been previously found to be reliable and valid for assessment of pain
reactivity in autism [56–58].
Pain reactivity was assessed for patients in three different
observational situations. 1) in day-care, where two caregivers
independently rated overall pain reactivity on a daily basis during
the month preceding the blood drawing; 2) at home, where
parents rated pain-related behavior during the same month as the
caregivers. In this situation, there were enough daily life situations
involving pain to distinguish reactions to a variety of types of
noxious and painful stimuli such as being burned, having internal
pain (tooth pain, ear infection, headache, etc.), and other
accidental painful stimuli (cutting, pinching, banging, etc.); 3)
during the blood drawing at a medical center, when a direct
clinical observation was conducted by a nurse and child
psychiatrist not belonging to the caregiver team. Normal controls
were similarly assessed for pain reactivity to the venepuncture
using the PL-BPRS. During the blood drawing, heart rate was
measured (with a stethoscope placed on the thorax considering
that some patients can react negatively when their wrist is touched)
immediately before and after the venepuncture (15-second
measurement period) in order to assess cardiovascular response
to the needle insertion. In addition, a checklist was used to indicate
the presence or absence of SIB, aggressive behaviors directed
against others, stereotyped behaviors and social withdrawal during
the blood drawing situation.
Table 2. Demographic Characteristics of Study Groups.
Variable Autism Comparison Group Group (n=73) (n=115) df Test Statistic (P values.0.10)
Sex M/F 49/24 75/40 1 x
2=0.02
Pubertal status* (Pre-pubertal/Pubertal/Post-pubertal) 32/16/25 45/27/43 2 x
2=0.32
Age, Mean6SD, (years)
Total group 11.764.5 12.765.9 186 t=1.37
Males 11.764.5 13.166.4 122 t=1.31
Females 11.664.5 12.365.5 62 t=0.63
Pre-pubertal 8.162.7 7.262.2 75 t=1.61
Pubertal 13.863.4 12.561.8 41 t=1.64
Post-pubertal 16.963.7 18.564.6 66 t=1.60
*Pre-pubertal=Tanner stage 1; Pubertal=Tanner stages 2, 3 and 4; Post-pubertal=Tanner 5.
doi:10.1371/journal.pone.0005289.t002
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The blood drawing for patients with autism (n=63) occurred at
the nearest general hospital rather than at the day-care facility so
that the research procedure was not associated with the therapeutic
milieu. Blood drawing for controls (n=115) occurred at the
Preventive Medical Center. The blood drawing followed a
standardized procedure to minimize and control the possible
stressful conditions. For all patients and controls, parents were
present during all the blood drawing and no white coats were worn
in the presence of the subject; the subjects stayed in a playroom for
15 minutes before the blood drawing and all phlebotomies were
performed by the same nurse, who was particularly experienced
with handicapped children. Blood was obtained from the
antecubital foci and collected in EDTA-containing tubes, between
8 and 9 am. After centrifugation (4uC, 15 min, 1000 xg), plasma
was acidified to pH 4.0 and frozen at 280uC until assayed. Plasma
BE concentrations were determined using a previously described
radioimmunoassay RIA procedure
58. Gel filtration on Se ´phadex
G75 was used to isolate a BE-containing fraction. After lyophiliza-
tion, the fraction was assayed using rabbit anti-serum directed
against the C-terminal portion of human BE. The assay is sensitive
(limit of detection, 5 pmoles/L) and reproducible (intra- and inter-
assay coefficients of variations, 5 and 6% respectively). Results of
plasma BE analysis are given only for the samples with acceptable
duplicate agreement (57 patients with autism, 103 controls).
Statistical analyses
Group comparisons of pain reactivity were assessed by x
2 test.
Relationships between behavioral pain reactivity across the
different observational situations were studied by contingency
analyses [59]. The Kolmogorov-Smirnov test indicated that
plasma BE levels were not normally distributed; thus all statistical
analyses were performed using log-transformed BE values.
Untransformed means and standard errors for BE levels are given
to allow comparisons to previous studies. Group and subgroup
comparisons of plasma BE levels were performed using analysis of
variance (ANOVA) and two-tailed t-test. Correlations were
determined by Spearman or Pearson correlation analyses as
appropriate. Based on reported variance in heart rate and plasma
BE levels, the study was designed to detect effect sizes of 0.5 or
greater.
Results
Relationships between descriptive variables and
behavioral pain reactivity or BE levels
There were no significant effects of IQ, age, sex, pubertal status
and medication status (neuroleptics or anticonvulsants) on
behavioral pain reactivity, regardless of the observational situation
(parental, caregiver, blood drawing). Significant relationships were
also not found between plasma BE levels and IQ, age, sex, or
medication status (neuroleptics or anticonvulsants). However,
there was a significant effect of puberty on plasma BE log-
transformed values (described in a following section).
Behavioral pain reactivity in the three observational
situations
The distributions of types of behavioral pain reactivity seen in
the three observational situations are presented in Table 4 and
Figure 1. A large proportion of individuals with autism displayed
low/absent pain reactivity according to the parental, caregiver and
blood drawing evaluations (68.6%, 34.2%, and 55.6%, respec-
tively). When behavioral pain reactivity to the venepuncture was
compared across the autistic and control groups (Figure 2), there
was a significant and substantial difference in the distribution of
pain reactivity responses (x
2 (df=4)=53.68, P,0.001). In
particular, there were more patients with autism and less controls
showing absence of pain reactivity than expected, whereas there
were more controls and less patients showing normal pain
reactivity than expected (x
2 (df=2)=33.1, P,0.0001). Similar
results were obtained when comparing drug-free individuals with
autistic disorder (n=47) to normal control subjects (n=115).
However, it is noteworthy that 22% individuals with autism
displayed normal pain reactivity to the venepuncture, and 15.9%
showed hyperreactivity. In addition, 60.3% of patients with autism
(and none of the normal controls) displayed certain autism-associated
behaviors immediately after the venepuncture (SIB, aggressive
behaviors directed against others, stereotyped behaviors and social
withdrawal were observed in 9.5%, 23.8%, 34.9%, and 38.1% of
patients, respectively). Similar behaviors following painful stimuli
were described by parents and caregivers (SIB, aggressive behaviors
directed against others, stereotyped behaviors, social withdrawal).
Parents and caregivers also reported that 9 out of the 22 verbal
Table 3. Types of Pain Reactivity assessed by the PL-BPRS (Pre-Linguistic Behavioral Pain Reactivity Scale).
Type I: Paradoxical pain reactivity
Apparent pleasure reaction to a painful stimulus (such as smiling or laughing).
Type II: Absence of pain reactivity
Absence of any reactions described in class IV with absence of nociceptive reflexes (such as absence of hand withdrawal reflex when burning oneself or absence of arm
withdrawal reflex from the needle during a blood drawing).
Type III: Hyporeactivity to pain
The individual with autism appears to withstand pain, but nociceptive reflexes to nociceptive stimuli are present. After noxious stimuli, the following possible
abnormalities are observed: incomplete pain reactivity compared to class IV, abnormally delayed reaction time.
Type IV: Normal pain reactivity
After painful stimuli the following reactions are observed: cries, screams, moaning, grimaces, reflexes of nociceptive withdrawal, lack of movement, body orientation
and glance towards the painful area (e.g., glance towards the venepuncture or sometimes away from it, also the individual with autism takes the observe r sh a n dt op u t
it on the painful area of his/her body, a behavior often found in some non-verbal patients with autism), stopping an activity in progress, reaction when the injured area
is touched, guarded body position when resting or in movement, spontaneous protection of the painful area. One of the important signs of pain reactivity for
individuals without verbal language is the immobilisation of the painful area of the body.
Type V: Hyperreactivity to pain
Disproportionate cries and screams given the painful stimulus (with hypersensitive light touch).
doi:10.1371/journal.pone.0005289.t003
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painful stimulus, but were unable to locate correctly the painful area.
A comparison using contingency analysis of the parental and
caregiver evaluations of overall behavioral pain reactivity type
showed no significant relationship between the ratings obtained in
the two situations. Similarly, no significant relationship was found
between the nurse/psychiatrist ratings during the blood drawing
situation and the parental or caregiver evaluations for overall
behavioral pain reactivity.
Heart rate response to venepuncture
Despite the absence of behavioral pain reactivity to the blood
drawing observed in many subjects of the autistic group (41.3%),
patients with autism displayed robust physiological responses to the
venepuncture with a significant increase in heart rate (reactional
tachycardia). Furthermore, patients with autism displayed a
significantly greater heart rate response to the venepuncture than
controls, and had also a significantly higher heart rate before and
after the venepuncture than controls (Table 5).
Relationships between diagnosis, autism severity and
plasma b-endorphin (BE) levels
A three-way ANOVA including group (patients, controls),
puberty (pre-pubertal, pubertal, post-pubertal) and sex factors
showed a significant effect of group (F1,146=37.22, P,0.001),
puberty (F2,146=6.04, P,0.01) and group interacting with puberty
(F2,146=5.80, P,0.01) (Figure 3). Patients with autism (n=57)
had significantly higher plasma BE levels (mean6SE, 231.5624.1,
versus 119.565.3 pmol/L) than controls (n=103). An ANOVA
including puberty and autism severity showed a significant effect of
Table 4. Evaluation of Behavioral Pain Reactivity in Three Different Observational Situations: Parental, Caregiver, Blood Drawing*.
Type of Behavioral Pain Reactivity
Type I Type II Type III Type IV Type V
Observational situation Paradoxical Absent Hyporeactivity Normal Hyperreactivity
Home setting/Parental evaluation in individuals with autism (n=73)
Overall pain reactivity 1 (1.4%) 2 (2.8%) 48 (65.8%) 20 (27.4%) 2 (2.8%)
Reaction to burning self 3 (4.1%) 0 (0%) 11 (15%) 57 (78.1%) 2 (2.7%)
Reaction to internal pain (tooth pain, ear infection, etc.) 0 (0%) 2 (2.8%) 34 (47.2%) 33 (45.8%) 3 (4.2%)
Reaction to other pain (accidents, banging self, etc.) 1 (1.4%) 1 (1.4%) 46 (64.8%) 19 (26.8%) 4 (5.6%)
Day-care/Caregiver evaluation of individuals with autism (n=73)
Overall pain reactivity 2 (2.7%) 3 (4.1%) 22 (30.1%) 43 (58.9%) 3 (4.1%)
Nurse/Psychiatrist evaluation during venepuncture
Individuals with autism (n=63) 4 (6.3%) 26 (41.3%) 9 (14.3%) 14 (22%) 10 (15.9%)
Normal controls (n=115) 1 (0.9%) 10 (8.7%) 35 (30.4%) 67 (58.3%) 2 (1.7%)
*Data are given as number of individuals (and % of group) assigned to each class of pain reactivity
doi:10.1371/journal.pone.0005289.t004
Figure 1. Overall Behavioral Pain Reactivity in Autism According to Rater/Setting. Types/classes of pain reactivity are described in detail in
Table 3 and the numerical data are presented in Table 4.
doi:10.1371/journal.pone.0005289.g001
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mean plasma BE levels observed in individuals with ‘‘severe’’
autism (244.2630.7, n=39) were higher than levels in individuals
with ‘‘mild’’ to ‘‘moderate’’ autism (214.4641.6, n=18) which
were higher than in normal controls (119.565.3, n=103). Plasma
BE levels were significantly higher in the severe autism subgroup
(t140=4.05, P,0.01) and in the mild/moderate autism subgroup
(t119=3.01, P,0.01) compared to the control group. Considering
that IQ scores were significantly negatively correlated with autism
severity (Spearman r=20.24, P,0.05), group mean plasma BE
levels in the severe and mild/moderate subgroups were also
compared using analysis of covariance (ANCOVA), with IQ
entered as a covariable. Similar, significant results were obtained
using the covariant analysis.
Relationships between plasma BE levels and pain
reactivity
Using contingency analyses, no significant relationships were
observed between plasma BE levels and behavioral pain reactivity
assessed in any of the three observational situations (caregiver,
parental, blood drawing) for patients with autism. Pain reactivity of
controls during the blood drawing was also not significantly related
to plasma BE levels. Levels of plasma BE were positively correlated
withheart rate before(r=0.28, P,0.05) and after the venepuncture
(r=0.29, P,0.05) in individuals with autistic disorder.
Discussion
We clearly show across the three observational situations that
abnormal behavioral responses to painful stimuli were highly
prevalent in individuals with autism of low to moderate
functioning. In general, there was a shift to hypo-reactive or
absent pain reactions in the autism group. Although this pattern of
observed behavior is consistent with a number of previous studies,
most prior reports did not distinguish pain reactivity from pain
sensitivity. As will be discussed, it is critical to keep this distinction
in mind and not to conclude that absence of behavioral pain
reactivity means absence of pain sensitivity. Indeed, one of our
major findings was that despite many subjects of the autism group
(41.3%) displaying absence of behavioral pain reactivity to the
venepuncture, individuals with autism showed a robust physiolog-
ical response with a significant reactional tachycardia to the
venepuncture. This suggests that individuals with autism experi-
enced the noxious stress of the venepuncture and that their
apparent behavioral analgesia could be related more to a different
Table 5. Heart Rates measured during Blood Drawing Procedure.
Heart Rate* Patients With Autism (n=63) Normal Controls (n=115) Test of Significance**
Heart rate immediately prior to venepuncture 93.262.2 83.361.1 t91=4.12, P,0.001
Heart rate immediately after venepuncture 99.662.5 84.661.2 t92=5.41, P,0.001
Heart rate response to venepuncture*** 6.462.5 1.360.8 t72=2.0, P,0.05
*Heart rate values (number of beats per minute) expressed as mean6SEM.
**Group mean comparison using a two-tailed unequal variance t-tests.
***Heart rate response to venepuncture (calculated as the heart rate taken a few seconds after the venepuncture minus heart rate a few seconds before the
venepuncture) was significant in the group of patients with autism (t62=2.62, P,0.05, matched-pairs t-test) and was not significant in the control group (t114=1.54,
P.0.05, matched-pairs t-test).
doi:10.1371/journal.pone.0005289.t005
Figure 2. Distribution of types of pain reactivity to venepuncture with nurse and child psychiatrist as observers. Types/class of pain
reactivity are described in detail in Table 3 and the numerical data are presented in Table 4.
doi:10.1371/journal.pone.0005289.g002
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Moreover, they displayed significantly higher stress responses to
the general blood drawing situation than controls (with higher
mean values of heart rate just before or after venepuncture, and
higher tachycardia to the venepuncture).
The greater heart rate response to venepuncture in the autistic
group compared to the control group may be a consequence of
several factors operating singly or in concert. Greater amounts of
situational anxiety in the autistic group are consistent with their
higher baseline heart rate and would be expected to increase pain
sensitivity [60]. Autistic individuals may also perceive the needle
insertion asmore invasive and more novel thancontrolindividuals. In
addition, they may be less able to regulate their emotional response to
pain or to express their noxious stress through verbal and non-verbal
communication, and also may be less capable of invoking adaptive
strategies such as deliberate self-distracting, exhibiting praiseworthy
stoicism, assuring oneself of the time-limited nature of the process, or
imagining comforting that will be shortly forthcoming.
However, a key question should be addressed: does the
reactional tachycardia to the venepuncture represent a valid
physiological indicator of pain? Indeed this reactional tachycardia
could rather reflect the stress of the autistic child of being held and
immobilized during the blood drawing. However, aggressively
restrictive measures were avoided and more specifically the
reactional tachycardia was calculated as the heart rate taken
immediately after the venepuncture minus the heart rate
immediately before the venepuncture when the child was already
being hold. Alternatively, the perception of the needle entering the
body or the sight of drawn blood could have been stressful. Stress
arising from the former possibility can not be ruled out; however,
the latter possibility can be ruled out because the nurse used a
Vacutainer system in such a way the child could not see the blood.
In addition to the physiological response to the venepuncture,
behavioral changes following the venepuncture or other painful
stimuli occurring at home and day hospital (SIB, aggressive
behaviors, stereotyped behaviors, social withdrawal) also suggest
that children with autism perceive pain, but do not express it in the
same way as normal children. Furthermore, our results indicated
that substantial proportions of individuals with autism did not
display low/absent overall pain reactivity according to the
parental, caregiver and blood drawing evaluations. More specif-
ically, a majority (78%) of the autistic individuals actually
displayed a normal behavioral reactivity to burning; this
underlines the importance of distinguishing different types of
painful stimuli. Also, our results indicate that 22% individuals with
autism displayed normal behavioral pain reactivity to the
venepuncture and 15.9% displayed hyperreactivity which is in
agreement with Nader et al.’s important study [61] finding on
average (mean values) normal behavioral responses or even
excessive facial pain reactivity (assessed by detailed coding of
videotapes using the Child Facial Coding System [62]) to the
venepuncture in 21 children with autism compared to 22 non-
impaired children. Taken together, these observations constitute a
clear challenge to theories of reduced pain sensitivity in autism.
Given our results, we can hypothesize that painful stimuli
provoke physical and psychic stress and that in autism this stress can
be manifested by physiological responses and expressed through
autistic behaviors. The different mode of pain expression in autism
may be related to 1) verbal communication impairments, 2) deficits
in non-verbal communication and body image problems (difficulty
locating the painful area), or 3) other cognitive problems such as: (a)
difficulty in establishing cause-effect relationships between the pain
sensation and the stimulus causing the pain, (b) problems
discriminating, representing and identifying sensations and emo-
Figure 3. Group mean plasma b-endorphin concentrations. Error bars represent SEM. Asterisks indicate significant differences within pubertal
subgroups between normal controls and patients with autism: *P,0.01,**P,0.001. Among the total group of individuals with autism, both pre-
pubertal and pubertal individuals had significantly higher b-endorphin levels than post-pubertal individuals (P,0.01).
doi:10.1371/journal.pone.0005289.g003
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perception of pain integrates sensorial, emotional, and cognitive
factors [63]), (c) problems of learning socially appropriate responses
to pain, as highlighted by Glover’s definition of pain in which
sensation, suffering, and learning are integral parts [64].
The notion of non-perception of pain (or decreased pain sensitivity)
in autism is similar to ideas once proposed for infants [65]. The denial
of infant pain was based on the idea of neurological and psychological
immaturity and a lack of knowledge of the particular pain semiology
related to the absence of verbal language. There are also striking
parallels between prior pain-related research in autism and in
schizophrenia. In both autism and schizophrenia [66–67], pain
insensitivity was widely accepted without being empirically established
through objective methods and opioid theories were posited.
However, certain studies have reported distorted perception of pain
(atypical pain including hyperreactivity to pain) related to social
communication impairments and a dissociation between decreased
behavioral and increased physiological responses in schizophrenia
[66–71], which suggests, as in our study, that apparent pain
insensitivity in schizophrenia is related to a different mode of pain
expression and response. Overall, the patterns of response to pain that
we observed, and the offered interpretations, appear largely consistent
with prior studies of pain in a range of relevant groups, including
young children, the severely neurological impaired, psychiatric
disorders, mentally retarded and the developmental delayed [41–
51]. In these groups, it appears likely that fundamental aspects of pain
sensitivity are intact and that altered responses to painful stimuli are
usually due to differences in experiencing and difficulties in
communicating the experience of pain. Autism appears to present a
special case where various factors seen operating in the groups listed
above can combine to lead to marked problems in this area. Thus,
difficulties in expressing pain in autistic individuals could arise from
general deficits in verbal and non-verbal communication and from
differences in the higher level processing and consideration of pain.
Another potentially important finding was that group patterns of
pain reactivity differed depending upon the observational situation.
The results underline the key role of the situation and the observers
in evaluations of pain reactivity. Our findings are in agreement with
Nader’s study [61] showing different results of behavioral pain
reactivity according to the observational situation. Thus, the rating
obtained by clinicians using the Child Facial Coding System during
theblooddrawingprocedurewasnotcorrelatedwitheitherparental
estimates of pain to the venepuncture or parental report of pain
sensitivity history [61]. This dependence of pain behavioral
response assessment on observer, and the potential influence of
the observer/rater and setting on the behavior itself, have been
previously examined and discussed [44].The different results
between the three observational situations underline the relational
aspect that seems to exist in the expression of behavioral pain
reactivity. This relational aspect manifests itself (a) in the patient
who may modulate his/her behaviors as a function of the
environment, and (b) in the observer who can perceive and
interpret, and thus score subjectively behavioral pain reactivity.
Behavioralpainreactivityinvolvesacommunicative dimensionwith
a person who expresses him/herself through a behavior related to a
situation, and another person who interprets and reacts to this
behavior. It should also be pointed out that the Nader study used a
stop-frame and slow-motion video display to assess facial expres-
sions during venpuncture, and actually found increased reactivity to
pain[61].Thus,theirresultsareconsistentwiththemainconclusion
of our study that individuals with autism do not have decreased
sensitivity to pain.
An additional important finding was the presence of significantly
higher plasma BE levels in patients with autism compared to normal
controls,anelevationthatwasassociatedwithautismseverity,butnot
with behavioral pain reactivity. The group elevation in BE is
consistent with our and several others’ prior studies [29,32–34]. The
absence of a group difference in post-pubertal subjects is consistent
with the blood drawing being less stressful for the older children and
young adults with autism, although the reasons for this are unclear.
The absence of an association between plasma BE and behavioral
pain reactivity is consistent with the fact that during stress exposure
peripheral BE is co-released with adrenocoticotrophin hormone
(ACTH) from the pituitary and does not cross the blood-brain
barrier. When measured in plasma, BE should be considered a stress
hormone [72–74] and not an indicator of central opioid functioning.
The positive correlations observed between plasma BE levelsand pre-
or post-venepuncture heart rate also tend to support this view. As
with the observed increased pre- and post venepuncture heart rates,
the increased group mean BE level in autism (which probably reflects
an increased activation of the hypothalamic-pituitary-adrenal axis)
appears to be associated with the stress of the blood drawing setting
and not with the observed pain-related behavior.
The apparent absence of real endogenous analgesia, as well as
the absence of clear benefits of opiate antagonist therapies and the
inconsistent results of studies measuring central opioid levels in
autism, all tend to weigh against opioid theories of autism.
However, our data do not allow us to definitively rule out the
theory of an excessive central BE activity in autism. Assessment of
possible central opioid alterations will require additional CSF
studies, neuroendocrine challenge studies, brain imaging or post-
mortem analyses. The increased plasma BE levels and heart rates
observed in individuals with autism during the blood-drawing
situation appear to reflect enhanced biological and physiological
stress responses which are dissociated from observable emotional
and behavioral reactions. Further research in larger groups is
urgently needed to characterize more fully pain sensitivity and
reactivity in autism, to understand the role of anxiety and stress
response system functioning in pain-related behavior, and to
improve the communication of distress in individuals with autism.
An increased awareness of the importance of stressful and painful
events in the care of individuals with autism is recommended. In
particular, a greater vigilance needs to be exercised in the care of
children with autism with regard to their exposure to painful
stimuli and their difficulty in expressing their behavioral response
to pain, knowing that altered or reduced behavioral pain reactivity
does not mean reduced pain sensitivity. We hope the present study
will contribute to a greater appreciation of the varieties of pain
expression in autism and will lead to a reconsideration of the
prevalent assumption that children with autism are insensitive or
indifferent to pain.
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